Is Sangani Hospital overvalued or undervalued?

As of 29 August 2025, Sangani Hospital's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, with a PE ratio of 35.59, an EV to EBITDA of 29.71, and a ROCE of 12.91%. In comparison to its peers, Sangani Hospital's valuation metrics are significantly more favorable; for instance, Max Healthcare is categorized as very expensive with a PE ratio of 92.6, while Apollo Hospitals, also attractive, has a PE of 69.47.
Despite a recent decline in stock price, Sangani Hospital has outperformed the Sensex over the past year, returning 59.29% compared to the Sensex's -2.88%. This performance, combined with its attractive valuation metrics, reinforces the conclusion that Sangani Hospital is currently undervalued in the market.